The University of Southampton
University of Southampton Institutional Repository

Letter to the editor. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease

Letter to the editor. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease
Letter to the editor. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease
TP53 abnormalities consistently emerge as the most significant adverse prognostic factor in multivariate analyses of both prospective and retrospective studies in early and advanced chronic lymphocytic leukaemia (CLL).1 In view of the higher response rates often achieved with alemtuzumab-containing regimens compared with alkylating agent and/or purine analogue therapy2 and the possibility of long-term disease-free survival following allogeneic transplantation in some patients, there is an increasing consensus for screening for TP53 abnormalities in CLL patients who fulfil the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) recommendations for initiating therapy.
0887-6924
212-214
Best, O.G.
993977d6-e16e-429e-8850-66338d3d264b
Gardiner, A.C.
3fdf7e69-2cbc-4693-9977-4f92829d5316
Davis, Z.A.
58858062-d4a2-45d5-8f54-c1f1ac944040
Tracy, I.
e3841053-f541-47a5-bbb6-6f364fcf99e5
Ibbotson, R.E.
300e87bd-1bf5-4be3-9b36-bd5844ed457f
Majid, A.
8c2bf857-5d12-4016-90d1-aacf9d1c89d3
Dyer, M.J.S.
14dd1a96-2bfb-4583-9c42-4aa54b611273
Oscier, D.G.
c2620a1d-25bb-48f7-9651-f5d023636381
Best, O.G.
993977d6-e16e-429e-8850-66338d3d264b
Gardiner, A.C.
3fdf7e69-2cbc-4693-9977-4f92829d5316
Davis, Z.A.
58858062-d4a2-45d5-8f54-c1f1ac944040
Tracy, I.
e3841053-f541-47a5-bbb6-6f364fcf99e5
Ibbotson, R.E.
300e87bd-1bf5-4be3-9b36-bd5844ed457f
Majid, A.
8c2bf857-5d12-4016-90d1-aacf9d1c89d3
Dyer, M.J.S.
14dd1a96-2bfb-4583-9c42-4aa54b611273
Oscier, D.G.
c2620a1d-25bb-48f7-9651-f5d023636381

Best, O.G., Gardiner, A.C., Davis, Z.A., Tracy, I., Ibbotson, R.E., Majid, A., Dyer, M.J.S. and Oscier, D.G. (2009) Letter to the editor. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia, 23 (1), 212-214. (doi:10.1038/leu.2008.260).

Record type: Article

Abstract

TP53 abnormalities consistently emerge as the most significant adverse prognostic factor in multivariate analyses of both prospective and retrospective studies in early and advanced chronic lymphocytic leukaemia (CLL).1 In view of the higher response rates often achieved with alemtuzumab-containing regimens compared with alkylating agent and/or purine analogue therapy2 and the possibility of long-term disease-free survival following allogeneic transplantation in some patients, there is an increasing consensus for screening for TP53 abnormalities in CLL patients who fulfil the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) recommendations for initiating therapy.

Full text not available from this repository.

More information

Published date: January 2009
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 341578
URI: https://eprints.soton.ac.uk/id/eprint/341578
ISSN: 0887-6924
PURE UUID: 8037a2ac-6b9d-432e-9159-d16826a54d85

Catalogue record

Date deposited: 30 Jul 2012 09:16
Last modified: 16 Jul 2019 21:57

Export record

Altmetrics

Contributors

Author: O.G. Best
Author: A.C. Gardiner
Author: Z.A. Davis
Author: I. Tracy
Author: R.E. Ibbotson
Author: A. Majid
Author: M.J.S. Dyer
Author: D.G. Oscier

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×